AbbVie Inc (ABBV)vsCG Oncology, Inc. Common stock (CGON)
ABBV
AbbVie Inc
$211.32
+3.64%
HEALTHCARE · Cap: $360.63B
CGON
CG Oncology, Inc. Common stock
$66.74
+3.07%
HEALTHCARE · Cap: $5.70B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 1513761% more annual revenue ($61.16B vs $4.04M). ABBV leads profitability with a 6.9% profit margin vs 0.0%. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
CGON
Avoid32
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-29.3%
Fair Value
$163.42
Current Price
$211.32
$47.90 premium
Intrinsic value data unavailable for CGON.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 34.1%
Conservative balance sheet, low leverage
Generating 4.9B in free cash flow
Revenue surging 409.2% year-over-year
Safe zone — low bankruptcy risk
Areas to Watch
6.9% margin — thin
Premium valuation, high expectations priced in
Earnings declined 88.7%
Distress zone — elevated risk
0.0% earnings growth
0.0% margin — thin
ROE of -21.7% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bull Case : CGON
The strongest argument for CGON centers on Revenue Growth, Altman Z-Score. Revenue growth of 409.2% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 100.0x leaves little room for execution misses.
Bear Case : CGON
The primary concerns for CGON are EPS Growth, Profit Margin, Return on Equity.
Key Dynamics to Monitor
ABBV profiles as a value stock while CGON is a hypergrowth play — different risk/reward profiles.
CGON carries more volatility with a beta of 0.70 — expect wider price swings.
CGON is growing revenue faster at 409.2% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 32/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
CG Oncology, Inc. Common stock
HEALTHCARE · BIOTECHNOLOGY · USA
CG Oncology, Inc. is a clinical-stage biotechnology company dedicated to developing groundbreaking cancer therapies, with its lead product, CG0070, an innovative oncolytic virus therapy targeting non-muscle invasive bladder cancer. The company is poised to address significant unmet medical needs in oncology, underscoring its potential to improve patient outcomes and reshape treatment approaches. As CG Oncology advances through clinical trials and critical regulatory milestones, it leverages its proprietary technology platform to distinguish itself in the competitive oncology sector. This strategic emphasis on pioneering therapeutic options presents an attractive opportunity for institutional investors interested in advancements that could significantly impact cancer care.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?